Results from laboratory experiments carried out by a team of molecular biologists at Saarland University have identified a strategy for overcoming resistance to a new therapeutic opportunity for prostate cancer patients and for potentially suppressing the migration of cancer cells.
The new therapeutic approach, which is currently being studied by numerous research groups, aims to destroy cancer cells by influencing cellular calcium distribution. However, the research team, supervised by Professor Richard Zimmermann and Dr Markus Greiner, found that in about half of the patients examined, a cellular mechanism was present that could impede the efficacy of the new therapy.
The molecular biologists discovered that this resistance was caused by an increased concentration of the protein Sec62 in the tumour cells. Results from their laboratory cell line experiments indicate that a pharmaceutically active agent previously used in the treatment of psychotic disorders can counteract the observed cellular resistance as well as supress cell migration. The research team has published its findings in the medical journal BMC Cancer.
Prostate cancer is the most common malignant tumour in men. A new therapeutic approach to combating the disease is currently the subject of international research. In recent years, US scientists have developed a number of analogues of thapsigargin that are capable of selectively killing tumour cells by emptying the calcium stores in these cells.
But recent research by scientists at Saarland University’s Faculty of Medicine in Homburg has demonstrated that in approximately half of the patients suffering from prostate cancer, the tumour cells can be expected to show a resistance to this new form of therapy.
‘The resistance mechanism is due to a higher concentration of the protein Sec62,’ explains Professor Richard Zimmermann. As a result of increased Sec62 levels the protein calmodulin can close the calcium leak channels more efficiently in the membrane of the important intracellular calcium store known as the endoplasmic reticulum. ‘This is why tumour cells with a higher concentration of Sec62 show greater resistance to treatment regimens based on thapsigargin analogues,’ says Zimmermann.
Working with tumour cell cultures in the laboratory, Zimmermann’s group at the Department of Medical Biochemistry and Molecular Biology has found a possible solution to the problem and their results have been published in the journal BMC Cancer. ‘Using tumour cell lines, we were able to show that a substance called trifluoperazine (TFP) was able to counteract the observed resistance. TFP has been used as an antipsychotic and was marketed in Germany under the brand Jatroneutral® where it was used in the treatment of psychotic disorders,’ explains Dr Markus Greiner, a member of Professor Zimmermann’s research team. ‘TFP binds directly to the protein calmodulin and thus impairs the calmodulin-mediated closure of the calcium channels,’ explains Greiner.
Sec62 has been shown to be an important tumour marker, i.e. a protein that occurs at enhanced concentrations in tumour cells, not only in prostate carcinomas, but also in thyroid and lung carcinomas. The Homburg researchers see a correlation between the presence of Sec62 protein and a more aggressive tumour and hence lower patient survival rates. The research team also measured increased Sec62 concentrations in tumours that had already metastasized.
‘Calcium is an important signalling molecule that regulates cell migration, which is itself an important contributor to tumour metastasis,’ says Markus Greiner. The calcium in the cells ensures that the cells can detect the direction in which they are migrating. If these tumour cells are treated with TFP, the calcium store will be emptied and the cells essentially lose their orientation. ‘This leads to an almost complete cessation of cellular migration,’ explains Greiner.
‘We propose a therapeutic approach based on TFP in combination with thapsigargin analogues. In future, this may be a therapeutic option for those many patients whose tumours have a high cellular concentration of Sec62, which might make them unsuitable for treatment with thapsigargin,’ says Greiner. The results obtained by the Homburg research team will now be evaluated in tumour model studies before any clinical trials can be proposed.
Original publication: Linxweiler M., Schorr S., Schäuble N., Jung M., Linxweiler J., Langer F., Schäfers H.-J., Cavaliè A., Zimmermann R., and Greiner M.: Targeting cell migration and Endoplasmic Reticulum stress response with calmodulin antagonists: Mimicking Sec62-depletion phenotypes by small molecule treatment, BMC Cancer, 2013, 13:574;
Contact: Prof. Dr. Richard Zimmermann: +49 (0)6841 162-6511
Dr. Markus Greiner: +49 (0)6841 162-6515 E-mail: firstname.lastname@example.org
Press photographs are available at http://www.uni-saarland.de/pressefotos and can be used free of charge.
Claudia Ehrlich | Universität des Saarlandes
Atom-Sized Craters Make a Catalyst Much More Active
30.11.2015 | SLAC National Accelerator Laboratory
Hydra Can Modify Its Genetic Program
30.11.2015 | Université de Genève (University of Geneva)
Before the fluid of the middle ear drains and sound waves penetrate for the first time, the inner ear cells of newborn rodents practice for their big debut. Researchers at Johns Hopkins report they have figured out the molecular chain of events that enables the cells to make “sounds” on their own, essentially “practicing” their ability to process sounds in the world around them.
The researchers, who describe their experiments in the Dec. 3 edition of the journal Cell, show how hair cells in the inner ear can be activated in the absence...
Planet Earth experienced a global climate shift in the late 1980s on an unprecedented scale, fuelled by anthropogenic warming and a volcanic eruption, according to new research published this week.
Scientists say that a major step change, or ‘regime shift’, in the Earth’s biophysical systems, from the upper atmosphere to the depths of the ocean and from...
The Fraunhofer Institute for Solar Energy Systems ISE has installed 70 photovoltaic modules on the outer façade of one of its lab buildings. The modules were...
Nerve cells cover their high energy demand with glucose and lactate. Scientists of the University of Zurich now provide new support for this. They show for the first time in the intact mouse brain evidence for an exchange of lactate between different brain cells. With this study they were able to confirm a 20-year old hypothesis.
In comparison to other organs, the human brain has the highest energy requirements. The supply of energy for nerve cells and the particular role of lactic acid...
In laser material processing, the simulation of processes has made great strides over the past few years. Today, the software can predict relatively well what will happen on the workpiece. Unfortunately, it is also highly complex and requires a lot of computing time. Thanks to clever simplification, experts from Fraunhofer ILT are now able to offer the first-ever simulation software that calculates processes in real time and also runs on tablet computers and smartphones. The fast software enables users to do without expensive experiments and to find optimum process parameters even more effectively.
Before now, the reliable simulation of laser processes was a job for experts. Armed with sophisticated software packages and after many hours on computer...
30.11.2015 | Event News
25.11.2015 | Event News
17.11.2015 | Event News
30.11.2015 | Trade Fair News
30.11.2015 | Trade Fair News
30.11.2015 | Trade Fair News